Topo IIβ Antibody (D-1): sc-365421

Topo IIβ Antibody (D-1) is a mouse monoclonal IgG3 antibody that detects Topo IIβ in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Topo IIβ is a crucial nuclear enzyme that plays a significant role in maintaining DNA topology during critical cellular processes, including DNA replication, transcription, and repair. Unlike its isoform Topo IIα, which is more widely expressed, Topo IIβ exhibits a unique expression pattern that is particularly important in the context of neuronal development and function. The distinct C-terminal region of Topo IIβ suggests that this enzyme may interact with specific proteins involved in neuronal signaling pathways, thereby influencing cellular responses to stress and contributing to the regulation of gene expression in the nervous system. Understanding the specific interactions and functions of Topo IIβ is vital, as dysregulation of this enzyme has been implicated in various diseases, including cancer and neurodegenerative disorders. Anti-Topo IIβ antibody (D-1) provides a reliable tool for researchers aiming to explore the intricate roles of this enzyme in cellular processes and its potential as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Topo IIβ Antibody (D-1) References:

1. XK469, a selective topoisomerase IIbeta poison.  |  Gao, H., et al. 1999. Proc Natl Acad Sci U S A. 96: 12168-73. PMID: 10518594
2. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.  |  Mensah-Osman, EJ., et al. 2002. Mol Cancer Ther. 1: 1321-6. PMID: 12516965
3. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.  |  Errington, F., et al. 2004. Cancer Chemother Pharmacol. 53: 155-62. PMID: 14504921
4. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.  |  Chikamori, K., et al. 2006. Leukemia. 20: 1809-18. PMID: 16932348
5. Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide.  |  Sunter, NJ., et al. 2010. J Nucleic Acids. 2010: PMID: 20847952
6. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.  |  Lin, RK., et al. 2013. J Biol Chem. 288: 7182-92. PMID: 23344961
7. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.  |  Kozuki, T., et al. 2017. Nucleic Acids Res. 45: 5995-6010. PMID: 28472494
8. Topoisomerase IIβ targets DNA crossovers formed between distant homologous sites to induce chromatin opening.  |  Miyaji, M., et al. 2020. Sci Rep. 10: 18550. PMID: 33122676
9. Disease-associated H58Y mutation affects the nuclear dynamics of human DNA topoisomerase IIβ.  |  Morotomi-Yano, K., et al. 2022. Sci Rep. 12: 20627. PMID: 36450898
10. Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ.  |  Morotomi-Yano, K. and Yano, KI. 2024. Int J Mol Sci. 25: PMID: 39409010

The preferred Topo IIβ antibody is Topo IIβ Antibody (H-8): sc-25330.